Two patients are described with severe and progressive rheumatoid arthritis in whom methotrexate was reintroduced despite previous methotrexate related pneumonitis.
In the treatment of severe erosive arthritis, a limited number of disease modifying drugs are available. When all avenues of treatment have led to intolerance or inefficacy in the patient with progressive disease, the question arises as to whether a previously useful but poorly tolerated drug can be safely reintroduced. Factors influencing this decision include the nature of the toxicity previously encountered, the severity of the patient's disease, and the current state of knowledge with respect to the agent in question.
We report here two patients with methotrexate pneumonitis in whom the drug was subsequently reintroduced and in whom pneumonitis did not recur.
Patients and methods

PATIENTS
For the purpose of diagnosis in this study, we used the criteria for methotrexate pneumonitis described by Searles and McKendry.' METHODS Gallium-67 scintigraphy was used to monitor the patients during rechallenge with methotrexate. This is a very sensitive but non-specific test for pulmonary inflammation which has been shown to correlate well with other indices of disease activity in inflammatory disorders of the lung, such as sarcoidosis and pulmonary fibrosis.2' A 67Ga scan may be abnormal before symptoms develop or before clinical or radiological signs are apparent.5 6 The 67Ga index used was based on the method described by Line et al2; the maximum possible gallium index is 400 U and a scan is considered to be abnormal if the index is greater than 50 U. Successful reintroduction ofmethotrexate after pneumonitis27 7-41, hydrogen carbonate 19 mmol/l, saturation 85%).
Results
PATIENT
A Swan Ganz catheter was inserted and showed low pulmonary artery wedge pressures, excluding pulmonary oedema (pulmonary artery wedge pressure 5 mmHg and pulmonary artery end diastolic pressure 5 mmHg). Blood and sputum cultures were consistently negative, as were serological tests for viral infection, fungal agents, and legionella.
Methotrexate and all other drugs (paracetamol, prochlorperazine, carbamazepine, and salbutamol) were discontinued and intravenous erythromycin, co-trimoxazole, and cefotaxime were given. Ventilation and inotropic support were subsequently required. Antibiotics were discontinued after 11 days.
The patient improved steadily and two weeks after admission her chest radiograph was normal (fig 2) . Over the next two years she had no further symptoms of respiratory disease and her chest radiograph remained normal. There was, however, a steady increase in the activity of the synovitis which confined her to bed. In July 1987, at the patient's request, 2-5 mg of methotrexate was given by mouth once a week. A baseline 67Ga scan at that time was normal. Since then 67Ga scans every six months have shown no evidence of recurrent pneumonitis. She is now maintained on a dose of 3 75 mg methotrexate by mouth, alternating with 5 mg weekly. Her synovitis remains under reasonable control and she leads an independent life, mostly in an electric wheelchair. PATIENT 2 In November 1984 a 66 year old woman with a 14 year history of rheumatoid arthritis characterised by widespread erosive joint destruction and high concentrations of rheumatoid factor and antinuclear antibodies was treated with methotrexate 7 In August 1986 she was admitted with a three week history of cough, increasing shortness of breath, yellow sputum and mouth ulcers. She had never smoked and had no previous history of respiratory disease. In addition to methotrexate she was receiving ibuprofen, folic acid, diazepam, fluoride, calcium supplements, and an antacid. Examination showed a fever of 38-5°C, pulse 120/minute, blood pressure 140/70 mmHg. Examination of the respiratory system showed a respiratory rate of 24/minute and decreased expansion bilaterally, but no added sounds. A chest radiograph showed a longstanding blunting of the costophrenic angles but no interstitial abnormality.
Haematological results showed haemoglobin 85 g/l, white blood cell count 4-1 x 109/1, 
